Prevalence of Hepatitis B Virus Infection in Patients with Rheumatic Diseases in Tohoku Area: A Retrospective Multicenter Survey
-
- Watanabe Ryu
- Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine
-
- Ishii Tomonori
- Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine
-
- Kobayashi Hiroko
- Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine
-
- Asahina Ichizo
- Yamagata Prefectural Central Hospital
-
- Takemori Hiromitsu
- Aomori Prefectural Central Hospital
-
- Izumiyama Tomomasa
- Higashisendai Riumatikanaika Clinic
-
- Oguchi Yoshito
- Oguchi Clinic
-
- Urata Yukitomo
- Department of Rheumatology, Seihoku Central Hospital
-
- Nishimaki Tomoe
- Nishimaki Clinic
-
- Chiba Katsumi
- Fukushima Daiichi Hospital
-
- Komatsuda Atsushi
- Akita University Graduate School of Medicine
-
- Chiba Noriyuki
- Morioka National Hospital
-
- Miyata Masayuki
- Department of Internal Medicine and Gastroenterology, Japanese Red Cross Fukushima Hospital
-
- Takagi Michiaki
- Department of Orthopaedic surgery, Yamagata University Faculty of Medicine
-
- Kawamura Osamu
- Ishinomaki Loyal Hospital
-
- Kanno Takashi
- Ohta Nishinouchi Hospital
-
- Hirabayashi Yasuhiko
- Hikarigaoka Spellman Hospital
-
- Konta Tsuneo
- Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
-
- Ninomiya Yukari
- Ninomiya Medical Clinic
-
- Abe Yoshiyuki
- Yamagata Prefectural Shinjo Hospital
-
- Murata Yuhji
- Kuroishi General Hospital
-
- Saito Yoshihiro
- Saito Clinic
-
- Ohira Hiromasa
- Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine
-
- Harigae Hideo
- Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine
-
- Sasaki Takeshi
- NTT East Japan Tohoku Hospital
この論文をさがす
抄録
Hepatitis B virus (HBV) reactivation has been increasingly recognized in patients receiving chemotherapy and immunosuppressive therapy; however, the prevalence of HBV infection and rate of HBV screening in patients with rheumatic diseases remains unclear. In this study, we aimed to assess the prevalence of HBV infection and fulminant HBV hepatitis in patients with rheumatic diseases. We also investigated the rate of HBV screening before immunosuppressive therapy in patients with rheumatic diseases. A retrospective questionnaire survey was conducted in the North-east area (Tohoku) of Japan. Questionnaires, comprising 6 questions, were sent to 318 rheumatologists in May 2010, and responses were gathered until June 2011. In total, 71 rheumatologists (22.3%) responded to the survey. We enrolled 7,650 patients with rheumatoid arthritis (RA) and 1,031 patients with systemic lupus erythematosus (SLE). When limited to institutes at which almost all (≥ 90%) patients were tested for HBV serology, 1.1% (40/3,580) patients with RA and 0.3% (3/1,128) patients with SLE were positive for hepatitis B surface antigen (HBsAg), and 25.2% (177/703) patients with RA and 13.7% (34/248) patients with SLE were positive for hepatitis B core antibody (HBcAb). About one-third of rheumatologists did not check HBsAg and more than half did not check hepatitis B surface antibody (HBsAb) or HBcAb at all before therapy. Fulminant HBV hepatitis was observed in 1 RA patient who was current HBV carrier. In conclusion, the prevalence of HBV infection is high in patients with RA and SLE. HBV screening before immunosuppressive therapy should be strictly performed.
収録刊行物
-
- The Tohoku Journal of Experimental Medicine
-
The Tohoku Journal of Experimental Medicine 233 (2), 129-133, 2014
東北ジャーナル刊行会